Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety pharmacology--current and emerging concepts.
Hamdam J, Sethu S, Smith T, Alfirevic A, Alhaidari M, Atkinson J, Ayala M, Box H, Cross M, Delaunois A, Dermody A, Govindappa K, Guillon JM, Jenkins R, Kenna G, Lemmer B, Meecham K, Olayanju A, Pestel S, Rothfuss A, Sidaway J, Sison-Young R, Smith E, Stebbings R, Tingle Y, Valentin JP, Williams A, Williams D, Park K, Goldring C. Hamdam J, et al. Among authors: stebbings r. Toxicol Appl Pharmacol. 2013 Dec 1;273(2):229-41. doi: 10.1016/j.taap.2013.04.039. Epub 2013 Jun 1. Toxicol Appl Pharmacol. 2013. PMID: 23732082 Review.
Failure to upregulate cell surface PD-1 is associated with dysregulated stimulation of T cells by TGN1412-like CD28 superagonist.
Thaventhiran T, Alhumeed N, Yeang HX, Sethu S, Downey JS, Alghanem AF, Olayanju A, Smith EL, Cross MJ, Webb SD, Williams DP, Bristow A, Ball C, Stebbings R, Sathish JG. Thaventhiran T, et al. Among authors: stebbings r. MAbs. 2014;6(5):1290-9. doi: 10.4161/mabs.29758. Epub 2014 Oct 30. MAbs. 2014. PMID: 25517314 Free PMC article.
Immunoglobulin G1 and immunoglobulin G4 antibodies in multiple sclerosis patients treated with IFNβ interact with the endogenous cytokine and activate complement.
Sethu S, Govindappa K, Quinn P, Wadhwa M, Stebbings R, Boggild M, Naisbitt D, Kimber I, Pirmohamed M, Park K, Sathish J. Sethu S, et al. Among authors: stebbings r. Clin Immunol. 2013 Aug;148(2):177-85. doi: 10.1016/j.clim.2013.05.008. Epub 2013 May 22. Clin Immunol. 2013. PMID: 23770627 Free PMC article.
CD28 Superagonistic Activation of T Cells Induces a Tumor Cell-Like Metabolic Program.
Thaventhiran T, Wong W, Alghanem AF, Alhumeed N, Aljasir MA, Ramsey S, Sethu S, Yeang HXA, Chadwick AE, Cross M, Webb SD, Djouhri L, Ball C, Stebbings R, Sathish JG. Thaventhiran T, et al. Among authors: stebbings r. Monoclon Antib Immunodiagn Immunother. 2019 Apr;38(2):60-69. doi: 10.1089/mab.2018.0042. Monoclon Antib Immunodiagn Immunother. 2019. PMID: 31009338 Free PMC article.
Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials--Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm.
Vessillier S, Eastwood D, Fox B, Sathish J, Sethu S, Dougall T, Thorpe SJ, Thorpe R, Stebbings R. Vessillier S, et al. Among authors: stebbings r. J Immunol Methods. 2015 Sep;424:43-52. doi: 10.1016/j.jim.2015.04.020. Epub 2015 May 7. J Immunol Methods. 2015. PMID: 25960173 Free PMC article.
After TGN1412: recent developments in cytokine release assays.
Stebbings R, Eastwood D, Poole S, Thorpe R. Stebbings R, et al. J Immunotoxicol. 2013 Jan-Mar;10(1):75-82. doi: 10.3109/1547691X.2012.711783. Epub 2012 Sep 11. J Immunotoxicol. 2013. PMID: 22967038 Free PMC article.
"Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics.
Stebbings R, Findlay L, Edwards C, Eastwood D, Bird C, North D, Mistry Y, Dilger P, Liefooghe E, Cludts I, Fox B, Tarrant G, Robinson J, Meager T, Dolman C, Thorpe SJ, Bristow A, Wadhwa M, Thorpe R, Poole S. Stebbings R, et al. J Immunol. 2007 Sep 1;179(5):3325-31. doi: 10.4049/jimmunol.179.5.3325. J Immunol. 2007. PMID: 17709549
89 results